the sooner the better only if the number of patients in the trial is large enough to show a significant effect. Otherwise, it's over. No further enrollment for moderate or severe, no trials for leronlimab vs remdesivir. No approval for covid-19. SP drops back to $1.80 or so. No uplisting. Then we wait 6 months for FDA to decide on combo-therapy for HIV. That's a pretty high risk game.

The advantage of waiting a little longer for full enrollment is that it is easier to show significant effects with a larger sample size.